Biodexa Pharmaceuticals Stock Is Tumbling Wednesday: What's Going On?
Biodexa Pharmaceuticals Stock Is Tumbling Wednesday: What's Going On?
Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) shares are trading lower Wednesday after the company announced $7 million in gross proceeds from warrant exercises.
Biodexa Pharmicals Plc（納斯達克股票代碼：BDRX）週三股價走低，此前該公司宣佈認股權證行使總收益爲700萬美元。
What Happened: Biodexa announced the exercise of previously issued warrants and an agreement between the company and several investors to exercise certain existing Series E and Series F warrants to purchase up to approximately 4.36 million of the company's American Depositary Shares (ADS).
發生了什麼：Biodexa宣佈行使先前發行的認股權證，並宣佈該公司與幾位投資者達成協議，行使某些現有的E系列和F系列認股權證，購買該公司最多約436萬股美國存托股票（ADS）。
The existing warrants, issued on December 21, 2023, had initial exercise prices of $2.20. The company said that each exercise occurred at a reduced exercise price of $1.50 per ADS. In consideration for the immediate exercise of the existing warrants for cash, the exercising holders will receive new unregistered warrants to purchase up to 6.54 million ADSs. The replacement warrants will have an exercise price of $2.50 per ADS.
2023年12月21日發行的現有認股權證的初始行使價爲2.20美元。該公司表示，每份ADS的行使價降低了1.50美元。作爲立即行使現有現金認股權證的回報，行使權持有人將獲得新的未註冊認股權證，用於購買多達654萬張美國存託憑證。替代認股權證的行使價爲每份ADS2.50美元。
Gross proceeds are expected to total $7 million. Biodexa said it plans to use the net proceeds from the offering to advance its clinical stage assets, as well as for working capital and general corporate purposes.
總收益預計爲700萬美元。Biodexa表示，計劃將此次發行的淨收益用於推進其臨床階段的資產，以及用於營運資金和一般公司用途。
The news comes after Biodexa shares rallied more than 83% on Tuesday after the company announced positive statistically significant findings from the Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis.
該消息是在Biodexa股價週二上漲超過83％之後發佈的，此前該公司宣佈了eRapa治療家族性腺瘤性息肉病的2期臨床試驗的積極統計學發現。
The results of the experiment showed eRapa, an oral tablet formulation of rapamycin, appeared safe and well-tolerated with a significant 24% reduction in the total polyp burden at six months compared with baseline, as well as an overall 83% non-progression rate.
實驗結果顯示，雷帕黴素口服片劑製劑eRapa看起來安全且耐受性良好，與基線相比，六個月後的息肉總負擔顯著減少了24％，總體非進展率爲83％。
BDRX Price Action: Biodexa shares were down 36% at $1.49 at the time of publication, according to Benzinga Pro.
BDRX價格走勢：根據Benzinga Pro的數據，Biodexa的股價在發佈時下跌了36％，至1.49美元。
譯文內容由第三人軟體翻譯。